- Previous Close
11.50 - Open
11.70 - Bid 11.70 x --
- Ask 11.80 x --
- Day's Range
11.70 - 11.70 - 52 Week Range
4.12 - 11.70 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
546.127M - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
79.59 - EPS (TTM)
0.15 - Earnings Date Dec 5, 2024 - Dec 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.
www.avidbio.com371
Full Time Employees
April 30
Fiscal Year Ends
--
Sector
--
Industry
Recent News: TEHP.F
View MorePerformance Overview: TEHP.F
Trailing total returns as of 11/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TEHP.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TEHP.F
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-101.27%
Return on Assets (ttm)
-3.05%
Return on Equity (ttm)
-115.84%
Revenue (ttm)
142.36M
Net Income Avi to Common (ttm)
-144.16M
Diluted EPS (ttm)
0.15
Balance Sheet and Cash Flow
Total Cash (mrq)
36.78M
Total Debt/Equity (mrq)
353.77%
Levered Free Cash Flow (ttm)
-201.62k